Concord Drugs is engaged in the manufacture of licensed pharmaceutical products based on approved formulations.
The company’s consolidated net profit surged 375% to Rs 0.19 crore on a 16.8% drop in revenue to Rs 10.28 crore in Q2 FY26 over Q2 FY25.
Click here to visit SEBI Scores